Cell Pathways develops and commercializes drugs for the prevention and treatment of cancer. The company has several compounds in various stages of clinical trials. Cell Pathways has research aimed at colon cancer, breast cancer, prostate cancer, and other areas.
Northwood led the company’s first two rounds of financing beginning in 1990 and participated in a number of subsequent rounds of financing. Cell Pathways became a publicly traded company in 1998. In 2003, Cell Pathways was acquired by OSI Pharmaceuticals, Inc. for stock, and Northwood liquidated its position through open market sales.